36 results about "Obese Mice" patented technology

The application discloses a polypeptide composition for treating obesity and related metabolic diseases and application thereof. The polypeptide composition comprises polypeptide 1 and polypeptide 2, wherein the amino acid sequence of the polypeptide 1 is shown as SEQ ID NO. 1, can be specifically combined with the CD105 receptor on the surface of MSCs and the AdipoR1 receptor of adipocytes; the amino acid sequence of the polypeptide 2 is shown as SEQ ID NO. 2, can target adipose tissue and regulate glycolipid metabolism. The polypeptide composition is combined with fat-derived mesenchymal stem cells (MSCs) and applied to a high-fat-diet obese mouse model, and the results show that the composition has a significant synergistic effect in reducing body fat, improving the morphology of adipose tissue, regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The application provides a new effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

This invention discloses the application of α-hydroxyisocaproic acid in weight loss and lipid reduction, belonging to the fields of biopharmaceutical manufacturing, biomedical applications, and functional food development. This invention confirms the application of α-hydroxyisocaproic acid in weight loss; this compound can inhibit weight gain in high-fat diet-induced obese mouse models, reduce body fat, and decrease the area of ​​adipocytes in high-fat diet-induced obese mouse models. Compared to GLP-1 receptor weight-loss drugs that reduce weight by suppressing appetite, the compound α-hydroxyisocaproic acid intervenes in and prevents obesity by accelerating fat metabolism, thereby achieving weight reduction. This invention provides a safe and effective new strategy for weight loss and lipid reduction.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The invention discloses a traditional Chinese medicine composition and application thereof in prevention or treatment of obesity, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from rhizoma pinellinae praeparata, caulis bambusae in taeniam, fructus aurantii immaturus, pericarpium citri reticulatae, poria cocos, radix scutellariae, fried hawthorn fruits, raw coix seeds, leeches, fresh ginger, Chinese dates and raw licorice roots according to specific weight parts. On the basis of a classic famous prescription, namely gallbladder-warming decoction, according to the traditional Chinese medicine pathology of qi loss of three jiao and damp heat-phlegm stasis-collateral obstruction, medicines such as scutellaria baicalensis, fried hawthorn, raw semen coicis, leech and the like are added, so that the fat-reducing gallbladder-warming decoction is formed. The composition has the effects of eliminating dampness and phlegm, clearing heat and eliminating blood stasis, and tonifying spleen and dredging collaterals. Animal experiments show that the traditional Chinese medicine composition can significantly reduce the weight, body fat and blood fat of obese mice and improve fatty degeneration of livers; clinical research shows that the weight, BMI, waistline, blood fat and traditional Chinese medicine syndromes of obese patients can be effectively improved, the total effective rate reaches 94.4%, and safety is good.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain of Caribik Meyer yeast and application thereof. The strain is isolated from natural plant enzymes. In an in-vitro test, the strain has relatively high TG (Triglyceride) degradation capacity and T-CHO (T-CHO) degradation capacity; in an in-vivo test, the enzyme prepared by fermenting a seed solution of the strain can effectively reduce the weight, fat coefficient and blood fat level of obese mice and relieve pathological changes of fatty liver, has no obvious toxic or side effect, and can be used as a candidate for replacing weight-reducing medicines, so that the enzyme has good practical application value.

The invention discloses an FSTL1 overexpression adeno-associated virus and application thereof, and aims to efficiently deliver a mouse source FSTL1 gene into mouse muscle cells by virtue of a virus infection mechanism by utilizing the targeting property of AAV1 type to muscle tissues. FSTL1 is overexpressed in mouse muscle tissue, muscle insulin signal transduction and glucose metabolism processes are adjusted from multiple dimensions of insulin signal channel activation, glucose transporter regulation and control and the like, and therefore the insulin sensitivity and glucose metabolism conditions of muscles in an obese mouse model are improved.

The invention belongs to the field of biological medicine, and particularly relates to a construction method and application of a spontaneous obesity model of a systemic GPX3 knock-gene mouse. The construction method comprises the following steps: preparing a precisely targeted GPX3 gene, knocking out a gene editing tool mixture of a specific segment (SEQ ID NO.1) of the GPX3 gene, transferring the gene editing tool mixture into a fertilized egg, and mating a mouse until a stably inherited GPX3 gene knockout homozygous mouse is obtained. The GPX3 is knocked out through the CRISPR / Cas9 technology, the spontaneous obese mouse model which cannot be achieved in the prior art is successfully obtained, the model can simulate obesity-related multi-organ lesions and diabetes mellitus progress, and a reliable tool is provided for obesity mechanism research and drug research and development.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

The present application relates to a kaurane diterpenoid compound D-33 extracted and separated from the roots of Euphorbia griffithii Hook., a preparation method and uses thereof. Bioactivity tests show that the compound D-33 has a significant weight loss effect in a high-fat diet-induced obese mouse model, can effectively activate uncoupling protein 1 (UCP1) in vitro, and can be used for preparing a thermogenic anti-obesity drug.

The invention relates to the field of medical preparations, in particular to application of ingenol in preparation of a medicine for treating liver injury of postmenopausal women. The ingenol intervenes in OVX to induce a postmenopausal obese mouse, and the ingenol is proved to be capable of remarkably reducing the weight and fat content of the mouse, reducing serum TC, TG and LDL-c level rise, improving hepatocyte swelling and reducing the number of liver fat droplets, and also capable of remarkably reducing serum AST and ALT level rise caused by OVX and relieving liver injury induced by OVX. Therefore, the ingenol can be used for effectively treating the liver injury of the postmenopausal women, and can be used for preparing a medicine for treating the liver injury of the postmenopausal women and a medicine for reducing the level of a liver injury marker in serum. The method can provide a new direction and strategy for future development and application of ingenol.

This invention discloses the application of sodium mannoside in the preparation of drugs for treating obesity and non-alcoholic fatty liver disease (NAFLD). Studies in this invention show that sodium mannoside has the effects of controlling body weight, improving glucose and lipid metabolism, enhancing insulin sensitivity, improving glucose tolerance, and preventing NAFLD. It can be used to prepare therapeutic drugs for metabolic diseases such as obesity caused by a long-term high-fat diet. Sodium mannoside can protect obese mice from liver lipotoxicity caused by a high-fat diet, providing more effective drugs for the prevention and treatment of obesity and NAFLD.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The invention provides application of propionyl carnitine in improvement of obesity and insulin resistance. Specifically, the invention finds that the propionyl carnitine has the effects of improving obesity and insulin resistance in a diet-induced obese mouse model, so that the application of the propionyl carnitine in treating obesity and obesity-related metabolic diseases is provided.

The present application relates to a kind of preparation method of corncob polysaccharide and its application as lipid inhibitor.A kind of preparation method of corncob polysaccharide includes the steps of preparing defatted corncob dry powder, alkali extraction crude polysaccharide, enzymatic hydrolysis purification, alcohol precipitation and refining, etc., through defatting, ultrasonic alkali extraction, enzymatic hydrolysis purification, low-temperature alcohol precipitation and freeze-drying etc., realize the efficient preparation of corncob polysaccharide from corncob, improve the comprehensive utilization value of corncob, promote the high-value utilization of bulk agricultural and sideline products;The application of polysaccharide component extracted from corncob as lipid inhibitor is also disclosed, the corncob polysaccharide component of the present application can effectively improve the weight gain and fat deposition of obese mice, providing a new solution for the prevention and treatment of obesity, which can be used as fat substitute or functional food ingredient of low-fat food.

This invention discloses the application of non-lactolytic streptococci in the preparation of products for preventing obesity, belonging to the field of animal nutrition and feed science and technology. This invention involves preparing non-lactolytic streptococci CCUG41503 into a concentration of 1×10⁻⁶. 8 When a CFU / mL bacterial suspension was administered via gavage to broilers and obese mice, *Streptococcus non-lactolyticus* CCUG41503 reduced abdominal fat percentage and the diameter and area of ​​adipocytes in broilers, and also reduced the weight of epididymal white fat and the diameter and area of ​​adipocytes in obese mice. This indicates that *Streptococcus non-lactolyticus* CCUG41503 has a fat-reducing effect and is widely applicable across multiple species.

The invention discloses application of 2-hydroxy-3-methylpentanoic acid in weight reduction and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The invention provides the application of the 2-hydroxy-3-methylvaleric acid and the derivative thereof in weight loss for the first time, and the compound can inhibit weight gain of a high-fat diet induced obesity model mouse, reduce body fat and reduce the fat cell area of the high-fat diet induced obesity model mouse. Compared with a GLP-1 receptor weight-reducing drug for reducing weight by inhibiting appetite, the compound 2-hydroxy-3-methylvaleric acid and the derivative thereof do not depend on appetite inhibition, and interfere and prevent obesity by accelerating fat metabolism, so that the effect of reducing weight is achieved; and side effects such as gastrointestinal discomfort and cardiovascular risk caused by appetite intervention are avoided. The invention provides a safe and effective new strategy for reducing weight and lipid.

The invention discloses application of aucubin in reducing fat deposition, and belongs to the field of biotechnology and animal husbandry application. The new application refers to application of aucubin in preparation of a composition for reducing fat deposition of non-human mammals. In particular, the composition can be used to induce and establish a standardized low fat deposition animal model or state, preferably a high fat diet induced obese mouse model (intragastric dose of 30 mg / kg body weight per day). In addition, the composition can also be used as a feed additive for non-human mammals. The aucubin is developed into a tool for constructing a standardized metabolism scientific research model for the first time, a brand new application scheme is provided for the aucubin as a safe and effective fat deposition regulating agent in livestock production, and the aucubin has important scientific research and industrial value.

The invention relates to the technical field of new application of medicines, and discloses application of nifedipine in preparation of weight-reducing medicines. Specifically, the invention discloses an application of nifedipine in preparation of a product for treating obesity or a product for reducing the weight of animals in a non-disease state, the molecular formula of nifedipine is C17H18N2O6, and experiments find that the weight of obese mice can be effectively reduced through administration treatment of nifedipine; after continuous administration for 8 weeks, the average body weight is reduced by 14.61% relative to the original body weight, and the compound can be used for preparing weight-reducing drugs.

The application belongs to the technical field of natural medicinal chemistry and enzyme inhibitor development, and particularly relates to a preparation method and application of an active ingredient of red bean. The active ingredient is (+) catechin 7-O-beta-D-glucopyranoside accurately separated from red bean. In vitro experiments prove that the active ingredient has strong inhibitory effect on alpha-glucosidase and pancreatic lipase. Cell and animal experiments further prove that the active ingredient can significantly inhibit the differentiation and lipid accumulation of 3T3-L1 preadipocytes, and can effectively reduce the body weight, body fat and blood lipid level of high-fat diet induced obese mice, and improve liver steatosis. The application plays a multi-target anti-obesity effect by synergistically inhibiting the digestion and absorption of sugar and fat, and has a wide application prospect in the preparation of medicines and functional foods for preventing and treating obesity, type II diabetes and other metabolic diseases.

The application belongs to the technical field of microorganisms, and provides GLP-1 / GIP recombinant engineering bacteria as well as a construction method and application thereof.The construction method comprises the following steps: taking a lactic acid bacteria constitutive expression plasmid as a skeleton, constructing a recombinant expression plasmid carrying a GLP-1 / GIP fusion target gene, introducing the recombinant expression plasmid into a host Lactobacillus plantarum, and obtaining the GLP-1 / GIP recombinant engineering bacteria; and the nucleotide sequence of the GLP-1 / GIP fusion target gene is shown in SEQ ID NO:1.The GLP-1 / GIP recombinant engineering bacteria not only have excellent in-vitro proliferation capacity and biological safety, but also exhibit significant effects of reducing blood sugar and weight, protecting liver and remodeling intestinal microecology in an obese mouse model.The application provides a new strategy and experimental basis for oral biological treatment of metabolic diseases, and has important theoretical value and broad clinical conversion prospects.

The application belongs to the technical field of medicine, and particularly relates to application of a 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or an internal racemate thereof, or an external racemate thereof, or an enantiomer thereof, or a diastereomer thereof, or a pharmaceutical composition with the active ingredient to preparation of a medicine for preventing or treating obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative has a significant curative effect on obesity and related metabolic diseases. After intragastric administration of the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative to obese mice induced by high-fat feed and high-fructose drinking water, after 6 weeks, compared with a high-fat control group, the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative inhibits more than 70% of weight gain of the mice, and there is no significant difference in food intake and water intake, and the 4-(4-diethylamino-1-methylbutylamino)-7-chloroquinoline derivative has a good clinical application prospect.

The invention discloses application of nolinoleic acid in preparation of a medicine for treating obesity, and belongs to the technical field of biological medicine. The molecular formula of the nolinoleic acid disclosed by the invention is C17H28O2. The nolinoleic acid plays a positive role in enhancing brown fat heat production and treating obesity, and animal model experiment verification shows that intervention of the nolinoleic acid reduces the weight of obese mice induced by high fat diet, improves the weight of brown fat tissues, improves sugar tolerance and insulin sensitivity, and can be used for treating obesity. And the brown fat heat production function phenotype and the overall metabolism level of mice are increased, which indicates that the nolinoleic acid has an enhancement effect on brown fat heat production and has a certain improvement effect on obesity. The research result of the invention provides a new treatment approach for obesity treatment.

The invention provides a traditional Chinese medicine composition for treating insulin resistance of obese children and a preparation method, and belongs to the technical field of traditional Chinese medicines. According to the traditional Chinese medicine composition, divaricate saposhnikovia roots and wrinkled gianthyssop herbs are used as monarch drugs, fructus gardeniae praeparatus is used as a ministerial drug, rhizoma coptidis and pericarpium citri reticulatae are used as adjuvant drugs, liquorice is used as a conductant drug, rhizoma nardostachyos and bitter herbs are used together, lifting and descending are combined, the effects of purging spleen and stomach fire, clearing damp and heat, eliminating dampness and reducing phlegm and regulating qi activity of the spleen and the stomach are achieved together, middle-jiao fire is cleared, qi activity is regulated, and therefore insulin sensitivity is improved, insulin resistance is improved, and toxic and side effects are reduced. And the physiological characteristic of delicate spleen and stomach of children is considered. When the traditional Chinese medicine composition is used for obese mice, the weight of the obese mice can be effectively reduced, glycolipid metabolism can be optimized, glucose tolerance and insulin resistance can be improved, the pathological morphology of epididymal adipose tissue can be reversed, the diversity of intestinal microbiota of the obese mice with insulin resistance can be increased, and the abundance of beneficial bacteria can be improved.